AQR Capital Management
KERX

AQR Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

AQR Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-28,069
Closed -$115K – 2420
2018
Q1 		$115K Hold
28,069
– – ﹤0.01% 2193
2017
Q4 		$131K Hold
28,069
– – ﹤0.01% 2190
2017
Q3 		$199K Buy
+28,069
New +$202K ﹤0.01% 2169
2015
Q1 		– Sell
-72,379
Closed -$1.02M – 2400
2014
Q4 		$1.02M Sell
72,379
-11,200
-13% -$174K ﹤0.01% 1632
2014
Q3 		$1.15M Sell
83,579
-10,400
-11% -$159K ﹤0.01% 1543
2014
Q2 		$1.45M Sell
93,979
-2,900
-3% -$41.1K ﹤0.01% 1453
2014
Q1 		$1.65M Sell
96,879
-25,700
-21% -$388K 0.01% 1422
2013
Q4 		$1.59M Hold
122,579
– – ﹤0.01% 1487
2013
Q3 		$1.24M Buy
122,579
+11,000
+10% +$97.9K ﹤0.01% 1559
2013
Q2 		$833K Buy
+111,579
New +$872K ﹤0.01% 1664

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management's KERX Position: Q2 2018 in Review

AQR Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2018, closing a stake of 28,069 shares — an estimated $115K sold.

AQR Capital Management first reported a position in KERX in Q2 2013 and held it in 10 quarters. The position peaked at $1.65M in Q1 2014. 132 funds tracked by Wall St. Rank hold KERX as of Q2 2018.

  • AQR Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • AQR Capital Management sold 28,069 Keryx Biopharmaceuticals Inc shares in Q2 2018, an estimated $115K.
  • AQR Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 10 quarters.
  • AQR Capital Management's Keryx Biopharmaceuticals Inc position peaked at $1.65M in Q1 2014.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2018.

Based on AQR Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.